Nationwide shortage of tuberculin skin test antigens : CDC recommendations for patient care and public health practice
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Nationwide shortage of tuberculin skin test antigens : CDC recommendations for patient care and public health practice

Filetype[PDF-310.59 KB]


English
Details You May Also Like

Details:

  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Description:
    Distributed via the CDC Health Alert Network

    June 6, 2019, 1130 ET (11:30 AM ET)

    CDCHAN-00420

    The Centers for Disease Control and Prevention (CDC) is expecting a 3 to 10 month nationwide shortage of APLISOL®, a product of Par Pharmaceuticals. APLISOL® is one of two purified-protein derivative (PPD) tuberculin antigens that are licensed by the United States Food and Drug Administration (FDA) for use in performing tuberculin skin tests. The manufacturer notified CDC that they anticipate a supply interruption of APLISOL® 5 mL (50 tests) beginning in June 2019, followed by a supply interruption of APLISOL® 1 mL (10 tests) in November 2019. The expected shortage of APLISOL® 1 mL (10 tests) could occur before November 2019, if demand increases before then. The 3-10 month timeframe for the nationwide shortage is the manufacturer’s current estimate and is subject to change.

    To monitor the status of this supply interruption, visit FDA’s “Center for Biologics Evaluation and Research (CBER)-Regulated Products: Current Shortages” webpage: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages.

  • Subjects:
  • Series:
    HAN ; 420
  • Document Type:
    HAN Health Advisory
  • Name as Subject:
  • Pages in Document:
    3 unnumbered pages
  • Issue:
    420
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov